Expression of mRNA for serglycin core protein and other platelet alpha granule proteins is increased in human erythroleukemia cells by phorbol myristate acetate.

Abstract:

:This study has determined the effects of phorbol-12-myristate-13-acetate (PMA) and dimethylsulfoxide (DMSO) on mRNA levels for the serglycin proteoglycan core protein in human erythroleukemia (HEL) cells. We have compared these changes to those for mRNA for other proteins which are known to be synthesized by HEL cells and megakaryocytes and are known to be localized to alpha granules within platelets. PMA caused a large increase in mRNA for serglycin within two hours of treatment of the cells, and the increase persisted for at least 72 hours. DMSO did not cause a significant change in mRNA levels. mRNA for platelet factor 4, transforming growth factor-beta, and P-Selectin (PADGEM, GMP-140) were also increased by PMA treatment. The mRNA for platelet factor 4 was substantially reduced in the presence of DMSO. The increase of mRNA for serglycin induced by PMA was consistent with our previous observation that synthesis of proteoglycans from [35S]sulfate was greatly stimulated by PMA in HEL cells. The data suggest that up-regulation of synthesis of proteoglycans is induced by PMA in cells which have the capacity to differentiate along the megakaryocytic lineage, as opposed to cell lines such as HL-60 in which proteoglycan synthesis is reduced in the presence of this differentiation-inducing agent.

journal_name

Leukemia

journal_title

Leukemia

authors

Schick BP,Thornton RD

subject

Has Abstract

pub_date

1993-12-01 00:00:00

pages

1955-9

issue

12

eissn

0887-6924

issn

1476-5551

journal_volume

7

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • Diminished TCR signaling in cutaneous T cell lymphoma is associated with decreased activities of Zap70, Syk and membrane-associated Csk.

    abstract::Malignant cells of patients with cutaneous T cell lymphoma (CTCL) are of monoclonal origin and of the CD4+/CD45RO+ subset. Since unlike their normal counterparts, triggering of their TCR/CD3 in vitro elicits only a weak mitogenic response, we set out to determine which of the signal transduction molecules initiated by...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400745

    authors: Fargnoli MC,Edelson RL,Berger CL,Chimenti S,Couture C,Mustelin T,Halaban R

    更新日期:1997-08-01 00:00:00

  • Cytogenetic evolution following the transformation of myelodysplastic syndrome to acute myelogenous leukemia: implications on the overlap between the two diseases.

    abstract::Cytogenetic evolution in the myelodysplastic syndrome (MDS) has been associated with an abrupt shift to acute myelogenous leukemia (AML). To investigate the 'evolution' of MDS to AML we compared the karyotypes of MDS patients at presentation and at development of AML. Of 170 patients with MDS who developed AML, 63 had...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Ghaddar HM,Stass SA,Pierce S,Estey EH

    更新日期:1994-10-01 00:00:00

  • Essential thrombocythemia--clinical features, therapy and follow-up of 12 cases.

    abstract::The authors analyzed twelve patients with symptomatic essential throthrombocythemia (E.T.) diagnosed from 1983 to 1991. Haemorrhagic and thrombotic phenomena were the main presenting features. Treatment consisted mostly of alpha-interferon (IFN-alpha 2b) subcutaneously in dosage ranging from 3 to 5 MU/m2 and hydroxyur...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Lopes E,Ribeiro MM,Silva MJ,Gandra M,Principe F,Granato C

    更新日期:1992-01-01 00:00:00

  • Constitutive SOCS-3 expression protects T-cell lymphoma against growth inhibition by IFNalpha.

    abstract::Signal transducer and activator of transcription (Stat)3 is constitutively activated in cutaneous T-cell lymphoma (CTCL), where it protects tumour cells against apoptosis. The constitutive activation of Stat3 leads to a constitutive expression of suppressor of cytokine signalling (SOCS)-3. In healthy cells, SOCS-3 is ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403610

    authors: Brender C,Lovato P,Sommer VH,Woetmann A,Mathiesen AM,Geisler C,Wasik M,Ødum N

    更新日期:2005-02-01 00:00:00

  • Abnormalities of chromosome 16q in myeloid malignancy: 14 new cases and a review of the literature.

    abstract::Fourteen patients with abnormalities of chromosome 16q, 13 with acute myelogenous leukaemia (AML), and one with refractory anaemia with excess of blasts (RAEB), are described. Seven patients had inv(16)(p13q22), two had del(16)(q22), and five had other abnormalities of 16q. Six of the seven patients with inv(16) had A...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:

    authors: Betts DR,Rohatiner AZ,Evans ML,Rassam SM,Lister TA,Gibbons B

    更新日期:1992-12-01 00:00:00

  • Short telomeres result in chromosomal instability in hematopoietic cells and precede malignant evolution in human aplastic anemia.

    abstract::In cell and animal models, telomere erosion promotes chromosomal instability via breakage-fusion-bridge cycles, contributing to the early stages of tumorigenesis. However, evidence involving short telomeres in cancer development in humans is scarce, epidemiological and indirect. Here we directly implicate telomere sho...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2011.272

    authors: Calado RT,Cooper JN,Padilla-Nash HM,Sloand EM,Wu CO,Scheinberg P,Ried T,Young NS

    更新日期:2012-04-01 00:00:00

  • Identification of a gene element essential for leukemia-specific expression of transgenes.

    abstract::Leukemia-specific promoters and enhancers for gene therapy had never been reported. Since the Wilms' tumor gene WT1 is overexpressed in almost all types of leukemia, WT1 is an ideal target of leukemia-specific therapy. To explore the possibility of gene therapy for leukemia using WT1 promoter and enhancer, their activ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403260

    authors: Hosen N,Yanagihara M,Nakazawa T,Kanato K,Nishida S,Shirakata T,Asada M,Masuda T,Taniguchi Y,Kawakami M,Tsuboi A,Ikegame K,Oka Y,Ogawa H,Kawase I,Oji Y,Sugiyama H

    更新日期:2004-03-01 00:00:00

  • BIOMED-I concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 Concerted Action Investigation of Minimal Residual Disease in Acute Leukemia: International Standardization and Clinical Ev

    abstract::The flow cytometric detection of minimal residual disease (MRD) in precursor-B-acute lymphoblastic leukemias (precursor-B-ALL) mainly relies on the identification of minor leukemic cell populations that can be discriminated from their normal counterparts on the basis of phenotypic aberrancies observed at diagnosis. Th...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402150

    authors: Lucio P,Gaipa G,van Lochem EG,van Wering ER,Porwit-MacDonald A,Faria T,Bjorklund E,Biondi A,van den Beemd MW,Baars E,Vidriales B,Parreira A,van Dongen JJ,San Miguel JF,Orfao A,BIOMED-I.

    更新日期:2001-08-01 00:00:00

  • Collection, analysis and transplantation of Ph-negative blood precursor cells in chronic myeloid leukemia.

    abstract::This work represents an update of our experience on mobilization and transplantation of peripheral blood progenitor cells (PBPC) collected during the early recovery phase after chemotherapy in patients with chronic myelogenous leukemia. The collection of Ph-negative precursor cells occurred in 13/19 (68%) patients mob...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Frassoni F,Carella AM

    更新日期:1996-06-01 00:00:00

  • Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia.

    abstract::Adults with acute lymphoblastic leukemia (ALL) do worse than children. From 7/2008 to 12/2014, Nordic and Baltic centers treated 1509 consecutive patients aged 1-45 years with Philadelphia chromosome-negative ALL according to the NOPHO ALL2008 without cranial irradiation. Overall, 1022 patients were of age 1-9 years (...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2017.265

    authors: Toft N,Birgens H,Abrahamsson J,Griškevičius L,Hallböök H,Heyman M,Klausen TW,Jónsson ÓG,Palk K,Pruunsild K,Quist-Paulsen P,Vaitkeviciene G,Vettenranta K,Åsberg A,Frandsen TL,Marquart HV,Madsen HO,Norén-Nyström U,Schmi

    更新日期:2018-03-01 00:00:00

  • Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML.

    abstract::Transformation of post-myeloproliferative neoplasms into secondary (s) AML exhibit poor clinical outcome. In addition to increased JAK-STAT and PI3K-AKT signaling, post-MPN sAML blast progenitor cells (BPCs) demonstrate increased nuclear β-catenin levels and TCF7L2 (TCF4) transcriptional activity. Knockdown of β-caten...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-018-0334-3

    authors: Saenz DT,Fiskus W,Manshouri T,Mill CP,Qian Y,Raina K,Rajapakshe K,Coarfa C,Soldi R,Bose P,Borthakur G,Kadia TM,Khoury JD,Masarova L,Nowak AJ,Sun B,Saenz DN,Kornblau SM,Horrigan S,Sharma S,Qiu P,Crews CM,Versto

    更新日期:2019-06-01 00:00:00

  • TET1 promotes growth of T-cell acute lymphoblastic leukemia and can be antagonized via PARP inhibition.

    abstract::T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological cancer characterized by skewed epigenetic patterns, raising the possibility of therapeutically targeting epigenetic factors in this disease. Here we report that among different cancer types, epigenetic factor TET1 is highly expressed in T-ALL a...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-020-0864-3

    authors: Bamezai S,Demir D,Pulikkottil AJ,Ciccarone F,Fischbein E,Sinha A,Borga C,Te Kronnie G,Meyer LH,Mohr F,Götze M,Caiafa P,Debatin KM,Döhner K,Döhner H,González-Menéndez I,Quintanilla-Fend L,Herold T,Jeremias I,Feuring-

    更新日期:2020-05-15 00:00:00

  • Progress against childhood and adolescent acute lymphoblastic leukaemia in the Netherlands, 1990-2015.

    abstract::We assessed the epidemiologic progress against childhood and adolescent acute lymphoblastic leukaemia (ALL) in the Netherlands over a 26 year period. ALL patients <18 years were selected from the Netherlands Cancer Registry and the Dutch Childhood Oncology Group. Trend analyses were performed over time and by age grou...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-020-01024-0

    authors: Reedijk AMJ,Coebergh JWW,de Groot-Kruseman HA,van der Sluis IM,Kremer LC,Karim-Kos HE,Pieters R

    更新日期:2020-08-21 00:00:00

  • Ectopic retroviral expression of LMO2, but not IL2Rgamma, blocks human T-cell development from CD34+ cells: implications for leukemogenesis in gene therapy.

    abstract::The occurrence of leukemia in a gene therapy trial for SCID-X1 has highlighted insertional mutagenesis as an adverse effect. Although retroviral integration near the T-cell acute lymphoblastic leukemia (T-ALL) oncogene LIM-only protein 2 (LMO2) appears to be a common event, it is unclear why LMO2 was preferentially ta...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404563

    authors: Pike-Overzet K,de Ridder D,Weerkamp F,Baert MR,Verstegen MM,Brugman MH,Howe SJ,Reinders MJ,Thrasher AJ,Wagemaker G,van Dongen JJ,Staal FJ

    更新日期:2007-04-01 00:00:00

  • C-Jun modulates apoptosis but not terminal cell differentiation in murine erythroleukemia cells.

    abstract::The proto-oncogene c-Jun has been implicated in the control of cell proliferation and differentiation and more recently in the regulation of apoptosis. We have previously reported the involvement of c-Jun in the erythroid differentiation block in murine erythroleukemia (MEL) cells. As reported here, we investigated th...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402350

    authors: Poindessous-Jazat V,Augery-Bourget Y,Robert-Lézénès J

    更新日期:2002-02-01 00:00:00

  • Therapeutic strategies for postremission treatment in childhood acute myeloid leukemia (AML). The AIEOP experience 1987-1991.

    abstract::From 1987 to 1990, intensive postremission chemotherapy was compared to autologous bone marrow transplant in previously untreated children with AML who received identical induction therapy with two courses of Daunorubicin (DNR) and conventional dose ARA-C (protocol AIEOP LAM 87). Overall, 121 of the 155 eligible patie...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:

    authors: Amadori S,Giona F,Giuliano M,Moleti ML,Pession A,Rolla M,Rondelli R,Testi AM,Mandelli F

    更新日期:1992-01-01 00:00:00

  • Identification of circulating CD10 positive T cells in angioimmunoblastic T-cell lymphoma.

    abstract::In most cases of lymphomas with blood dissemination, the careful cytological analysis of peripheral blood smears provides a rapid orientation to diagnosis, even if the final subtyping is achieved by histology and eventually other techniques. Here, we evaluated if the analysis of blood smears may suggest the blood diss...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404013

    authors: Baseggio L,Berger F,Morel D,Delfau-Larue MH,Goedert G,Salles G,Magaud JP,Felman P

    更新日期:2006-02-01 00:00:00

  • A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia.

    abstract::Chronic myelomonocytic leukemia (CMML) is a complex clonal hematological disorder classified among myelodysplastic (MDS)/myeloproliferative neoplasms. Prognosis is poor and there is a lack of effective treatments. The hypomethylating agent decitabine has shown activity against MDS and elderly acute myeloid leukemia, b...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究

    doi:10.1038/leu.2017.186

    authors: Santini V,Allione B,Zini G,Gioia D,Lunghi M,Poloni A,Cilloni D,Sanna A,Masiera E,Ceccarelli M,Abdel-Wahab O,Terenzi A,Angelucci E,Finelli C,Onida F,Pelizzari A,Ferrero D,Saglio G,Figueroa M,Levis A

    更新日期:2018-02-01 00:00:00

  • Mesenchymal stem cells in suppression or progression of hematologic malignancy: current status and challenges.

    abstract::Mesenchymal stem cells (MSCs) are known for being multi-potent. However, they also possess anticancer properties, which has prompted efforts to adapt MSCs for anticancer therapies. However, MSCs have also been widely implicated in pathways that contribute to tumor growth. Numerous studies have been conducted to adapt ...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/s41375-018-0373-9

    authors: Lee MW,Ryu S,Kim DS,Lee JW,Sung KW,Koo HH,Yoo KH

    更新日期:2019-03-01 00:00:00

  • B-cell regulator of immunoglobulin heavy-chain transcription (Bright)/ARID3a is a direct target of the oncomir microRNA-125b in progenitor B-cells.

    abstract::B-cell acute lymphoblastic leukemia (B-ALL) is often associated with chromosomal translocations leading to the deregulation of proto-oncogenes. MicroRNAs can also be affected by chromosomal alterations and thus contribute to carcinogenesis. The microRNA, miR-125b-1, is overexpressed in B-ALL cases with the t(11;14)(q2...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2012.95

    authors: Puissegur MP,Eichner R,Quelen C,Coyaud E,Mari B,Lebrigand K,Broccardo C,Nguyen-Khac F,Bousquet M,Brousset P

    更新日期:2012-10-01 00:00:00

  • Prognostic value of residual normal metaphases in acute myelogenous leukemia patients presenting with abnormal karyotype.

    abstract::Two hundred and forty-four untreated acute myelogenous leukemia (AML) patients with unfavorable karyotypes and 109 others with favorable aneuploid karyotypes were used to evaluate the prognostic significance of having both normal and abnormal metaphases (AN) vs only abnormal metaphases (AA) at AML presentation. The AA...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Ghaddar HM,Pierce S,Reed P,Estey EH

    更新日期:1995-05-01 00:00:00

  • Frequent detection of minimal residual disease by use of the polymerase chain reaction in long-term survivors after bone marrow transplantation for chronic myeloid leukemia.

    abstract::The polymerase chain reaction (PCR) allows the detection of minimal amounts of nucleic sequences and has been successfully used to test for the chronic myeloid leukemia-specific bcr/abl transcripts. We studied blood samples from 17 patients who had undergone allogeneic bone marrow transplantation for CML, using a modi...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Pignon JM,Henni T,Amselem S,Vidaud M,Duquesnoy P,Vernant JP,Kuentz M,Cordonnier C,Rochant H,Goossens M

    更新日期:1990-02-01 00:00:00

  • P-glycoprotein expression as unfavorable prognostic factor in acute myeloid leukemia.

    abstract::In order to further define the role of the MDR1 gene in acute myeloid leukemia (AML), we determined the association between the presence of P-glycoprotein on leukemic cells and the efficacy of therapy in patients with AML. Immunocytochemistry with monoclonal antibody C219 was performed to demonstrate the presence of P...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Zöchbauer S,Gsur A,Brunner R,Kyrle PA,Lechner K,Pirker R

    更新日期:1994-06-01 00:00:00

  • Establishment and characterization of a murine megakaryoblastic cell line growing in protein-free culture (L8057Y5).

    abstract::A murine megakaryoblastic cell line growing in protein-free culture (L8057Y5) was established from an experimentally induced murine leukemia (MK8057). Most of the Y5 cells were small and blast-like, with 2-4N in DNA content. Also, large cells possessing a lobulated nucleus characteristic of megakaryocytes, which showe...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Sasaki H,Kajigaya Y,Hirabayashi Y,Funabiki T,Inoue T,Yokota T,Ikuta K,Arai K,Matsuyama S

    更新日期:1991-05-01 00:00:00

  • A classification based on T cell selection-related phenotypes identifies a subgroup of childhood T-ALL with favorable outcome in the COALL studies.

    abstract::During T cell selection in the thymic cortex more than 90% of the thymocytes are eliminated by apoptosis. Based on this biology, we propose to define blasts of T cell acute lymphoblastic leukemia (ALL) with the phenotype of cortical thymocytes (CD1+ and/or CD4+ 8+) as selection-related (SR) and all other T-ALL immunop...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401382

    authors: Niehues T,Kapaun P,Harms DO,Burdach S,Kramm C,Körholz D,Janka-Schaub G,Göbel U

    更新日期:1999-04-01 00:00:00

  • Gene deletion explains both in vivo and in vitro generated chromosome 2 aberrations associated with murine myeloid leukemia.

    abstract::Ninety-five percent of radiation-induced murine myeloid leukemias contain chromosome 2 aberrations. A dominant molecular defect has not yet been identified: both deletions and breakpoint-specific events have been postulated. We have generated a model in which chromosome 2 lesions have been generated in vitro in a clon...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Alexander BJ,Rasko JE,Morahan G,Cook WD

    更新日期:1995-12-01 00:00:00

  • A robust xenotransplantation model for acute myeloid leukemia.

    abstract::Xenotransplantation of human acute myeloid leukemia (AML) in immunocompromised animals has been critical for defining leukemic stem cells. However, existing immunodeficient strains of mice have short life spans and low levels of AML cell engraftment, hindering long-term evaluation of primary human AML biology. A recen...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2009.143

    authors: Sanchez PV,Perry RL,Sarry JE,Perl AE,Murphy K,Swider CR,Bagg A,Choi JK,Biegel JA,Danet-Desnoyers G,Carroll M

    更新日期:2009-11-01 00:00:00

  • Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa.

    abstract::We assessed clinical results in 145 patients with chronic myeloid leukaemia in chronic phase who satisfied criteria for interferon-alpha failure and were thus eligible for treatment with imatinib at the Hammersmith Hospital. We used univariate and multivariate analyses to develop a risk score based on features defined...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402996

    authors: Marin D,Marktel S,Bua M,Szydlo RM,Franceschino A,Nathan I,Foot N,Crawley C,Na Nakorn T,Olavarria E,Lennard A,Neylon A,O'Brien SG,Goldman JM,Apperley JF

    更新日期:2003-08-01 00:00:00

  • Deficient tumor-infiltrating T-lymphocyte response in malignant lymphoma: relationship to HLA expression and host immunocompetence.

    abstract::Tumor-infiltrating T-lymphocytes (T-TIL) are putative mediators of tumor containment that exhibit unique specificity for autologous tumor cells. The magnitude of T-TIL response in biopsy specimens from patients with B-cell lymphoma has been suggested as an independent predictor of clinical outcome. Since recognition o...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: List AF,Spier CM,Miller TP,Grogan TM

    更新日期:1993-03-01 00:00:00

  • A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis.

    abstract::Myelofibrosis (MF; primary or post-essential thrombocythemia/polycythemia vera) is incurable clonal myeloproliferative disorder, with no effective treatment. Epigenetic changes play an important role in cancer pathogenesis through transcriptional silencing of critical tumor suppressor genes. We conducted a phase-II st...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2008.91

    authors: Quintás-Cardama A,Tong W,Kantarjian H,Thomas D,Ravandi F,Kornblau S,Manshouri T,Cortes JE,Garcia-Manero G,Verstovsek S

    更新日期:2008-05-01 00:00:00